Equity
Additional Paid-In Capital
Thermo Fisher Scientific Additional Paid-In Capital increased by 0.8% to $18.71B in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
A consistent increase is common for growth companies that frequently issue stock-based compensation or raise capital through equity markets.
Detailed definition
This represents the excess amount paid by investors for common shares above their stated par value. It is a critical com...
Peer comparison
This is a standard equity account for all publicly traded corporations, representing the cumulative historical premium paid by investors.
Metric ID:
equity_additional_paid_in_capital_common_stockHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $18.56B | $18.71B |
| QoQ Change | — | +0.8% |
Range$18.56B – $18.71B
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's additional paid-in capital?
- Thermo Fisher Scientific (TMO) reported additional paid-in capital of $18.71B in Q1 2026.
- What does additional paid-in capital mean?
- The total amount of capital received from shareholders in excess of the nominal par value of the stock.